RE:RE:call me crazy but ill take on a bit more risk at this level ",,Hummm,,,, Let me see,,,,,I get a total of ruffly 1,170,000,000 billion shares in the Biodexa structure fully dilluted when the warranats are exercised and all is said and done Yes,,that is a total of 1.17 billion,,,,,,,,lmao,,,,,,incredible! ,,,so for existing BTI shareholders to equal $0.50/share in the presnt, down the road a Boidexa ADR would have to be trading at ruffly $10 per share!." The deal is potentially very big and very bold, narmac. There is substantial dilution on one side but a potential multi-asset, multi-platform therapeutics company on the other that can stand on it own. There is risk with clinical assets but if it all comes together the following is possibe. Trying to cobble information together quickly this is a vision of what may result. We may need some time to see how acurate this is. The webinar will hopefully helps draw a clear vision. Time will tell all.
Biodexa:
1) NASDAQ listing.
2) Potential >US$100 million market cap near-term of more interest to larger capital market participants.
3) Backing of US Ladenberg Thalmann. According to Wikepedia Ladenberg Thalmann has 4,000 financial advisors and manages US$125 billion in client assets.
4) Frequent expected newsflow from partnerships to multiple clinical stage assets.
5) Scale and infrastructure to more efficiently develop a large pipeline internally as a therapeutics company.
6) Clinical hard data valuation milestones obtainable while xB3/Q-Sphera advance to the clinic over the next two years or more. Markets for Biodexa's near-term clinical trial programs(panobinostat, EGF) total an expected C$12 billion per year and growing. The glioblastoma market is expected to be worth C$5.67 billion per year in 2028. The Optic Neuritis market is C$275 million in 2022. Guillian-Bar therapy market is expected to be C$917 million in 2027. CIDP therapy market is expected to be C$5.265 billion at the end of 2023. Partnership agreements are also anticipated to support newsflow.
7) Potential 2 years cash in the near term in difficult market. There is 30 business days until the expiration of the J&J option. Neuremedy has an option that can be exercised and monitized. There are also potential milestone payments from partners as well as outstanding warrants and options. New partnerships can be signed. The breadth of the asset base could create multiple monitization opportunities if internal funding needed.
8) As Biodexa's clinical stage assets potentially reach the market revenue can support a potential broad pipeline helping to minimize dilution. Again, markets for Biodexa's near-term clinical trial programs(panobinostat, EGF) total an expected C$12 billion per year and growing.
9) Q-Sphera: "No other company or acedemic institution has been able to do what we've done. We could have the world's first long acting injectable protein. Let me just say that it is not often that small companies like ours make these kinds of scientific leaps. This really is our Watson and Crick moment." Stephen Stamp CEO Midatech June 17, 2021
"In 2020, the top 10 mAbs recorded aggregate sales of US$74.9 billion1 and all mAbs US$154 billion1 globally." June 17, 2021".
News release, "On 17 June 2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling".
10) Hunter is reaffirmed as xB3's lead asset in the merger. If Chiesi encountered a roadblock would Hunter, which is also an LSD, be nominated as xB3's lead assets? Chiesi recently submitted Fabry for US FDA approval and expects approval in 2023 making it a strategic player in the LSD space. Biodexa will be presenting preclinical Hunter data in Q2 2023. What's this new data about given the previous data BTI has presented? Do we have improved second-generation LSD asset to take on Denali which has helped prove LSDs in humans? Could Biodexa leap-frog Denali? Biodexa has the capability to advance clinical trials itself. Biodexa could enter a more substantive strategic deal with Chiesi in the LSD and even rare disease space. Oxyrane also has an interesting potential LSD opportunity.
11) Biodexa has cancer assets and expertise that could be used with xB3 that may support an interesting strategic alliance in cancer or combination therapies.
panobinostat, lomustine, xB3-bevacizumab
Midatech's lead drug currently in clinical trials is
panobinostat and seeks to bypass the blood-brain barrier directly into the brain tumor. The current clinical trial will study
panobinostat alone and in combination with
lomustine. BTI has reseached xB3 with bevacizumab for this same tumor. Could these drugs together, with Midech's and BTI's delivery technology, solve the problems of previous trials? "There are several potential reasons for the lack of activity with this combination. The dose of panobinostat used in this study was the maximum tolerated dose determined in our preliminary phase I study.19 Even though this dose is being explored in hematologic malignancies, it may be too low to achieve adequate tumor concentrations in the brain. This issue is compounded by the limited penetration of panobinostat across the blood-tumor barrier, a problem that is further exacerbated by combining it with bevacizumab, which reduces vascular permeability. In contrast, lomustine, which does penetrate the blood-tumor barrier, was successfully combined with bevacizumab for treatment of recurrent GBM.27 This difference underscores the need to combine bevacizumab with agents that have good blood-tumor barrier penetration. In addition, there are no preclinical data exploring the activity of the combination of panobinostat and bevacizumab in GBM models." Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma | Neuro-Oncology | Oxford Academic (oup.com)
12) Midatech's lead drug is a repurposed drug already approved for multilple myeloma. Imaging data concerning tissue distribution at the tumor site in humans, consistent cancer killing data from multiple cell lines, preclinical data, and trial data in humans to date may support high confidence for Biodexa's lead drug MTX-110. Review Midatech presentations for specifics.